+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Fatigue - Pipeline Review, H1 2017

  • ID: 4091143
  • Report
  • February 2017
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BioLite Inc
  • Biovista Inc
  • Chronos Therapeutics Ltd
  • Grifols SA
  • Hemispherx Biopharma Inc
  • K-Pax Pharmaceuticals Inc
  • MORE
Fatigue - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Fatigue - Pipeline Review, H1 2017, provides an overview of the Fatigue (Central Nervous System) pipeline landscape.

Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Fatigue - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fatigue (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fatigue (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 1 and 3 respectively.

Fatigue (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fatigue (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fatigue (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fatigue (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fatigue (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fatigue (Central Nervous System).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fatigue (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fatigue (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • BioLite Inc
  • Biovista Inc
  • Chronos Therapeutics Ltd
  • Grifols SA
  • Hemispherx Biopharma Inc
  • K-Pax Pharmaceuticals Inc
  • MORE
Introduction

Fatigue - Overview

Fatigue - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Fatigue - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fatigue - Companies Involved in Therapeutics Development

Aoxing Pharmaceutical Company Inc

BioLite Inc

Biovista Inc

Chronos Therapeutics Ltd

Grifols SA

Hemispherx Biopharma Inc

K-Pax Pharmaceuticals Inc

Merz Pharma GmbH & Co KgaA

MultiCell Technologies Inc

Fatigue - Drug Profiles

(lofepramine hydrochloride + phenylalanine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-1402 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

caffeine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPAX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MRZ-9547 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant A1PI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fatigue - Dormant Projects

Fatigue - Product Development Milestones

Featured News & Press Releases

Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients

Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME

Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen

Jul 25, 2016: Hemispherx Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe

Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology

May 23, 2016: Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke

Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen

Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study

Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms

Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe

Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division’s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations

May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations

May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Fatigue, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Fatigue - Pipeline by Aoxing Pharmaceutical Company Inc, H1

Fatigue - Pipeline by BioLite Inc, H1

Fatigue - Pipeline by Biovista Inc, H1

Fatigue - Pipeline by Chronos Therapeutics Ltd, H1

Fatigue - Pipeline by Grifols SA, H1

Fatigue - Pipeline by Hemispherx Biopharma Inc, H1

Fatigue - Pipeline by K-Pax Pharmaceuticals Inc, H1

Fatigue - Pipeline by Merz Pharma GmbH & Co KgaA, H1

Fatigue - Pipeline by MultiCell Technologies Inc, H1

Fatigue - Dormant Projects, H1

List of Figures:

Number of Products under Development for Fatigue, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • Aoxing Pharmaceutical Company Inc
  • BioLite Inc
  • Biovista Inc
  • Chronos Therapeutics Ltd
  • Grifols SA
  • Hemispherx Biopharma Inc
  • K-Pax Pharmaceuticals Inc
  • Merz Pharma GmbH & Co KgaA
  • MultiCell Technologies Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll